1-di(sec-butyl)phosphinoylpentane | 52911-13-4

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦及其衍生物
• 英文名称: 1-di(sec-butyl)phosphinoylpentane
• 英文别名: 1-di-sec-butylphosphoryl pentane；Phosphine oxide, bis(1-methylpropyl)pentyl-；1-di(butan-2-yl)phosphorylpentane
• CAS: 52911-13-4
• 化学式: C₁₃H₂₉OP
• 分子量: 232.346
• InChiKey: MOISWZCRUUWWBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
  申请人：Wei Edward T.

  公开号：US20150164924A1

  公开（公告）日：2015-06-18

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and/or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.

  本发现通常涉及治疗化合物领域。更具体地，本发现涉及如下所述的某些二异丙基磷酰基烷烃，即DIPA-1-5、DIPA-1-6、DIPA-1-7、DIPA-1-8和DIPA-1-9，以下统称为“DIPA化合物”，这些化合物在治疗包括但不限于感觉不适（例如由刺激、瘙痒或疼痛引起）、皮肤感觉异常、皮炎、眼部疼痛和不适、热感不适、热应激、潮红和/或盗汗（血管运动症状）、术后低体温、麻醉后颤抖、疲劳、疲倦、抑郁、认知功能障碍以及增强认知功能等疾病（例如疾病）的治疗中具有用途。申请人发现将DIPA化合物局部传递至上眼睑和/或面部皮肤对行为具有警觉和增强效果，并可用于给予一种化妆上的焕然一新的外观，提高精神警觉度，减轻疲劳，并提高工作产出。本发现还涉及包含此类化合物的药物组合物，以及此类化合物和组合物的用途，例如在治疗、神经病痛诊断和TRPM8功能研究中的应用。
• Chemical inhibitors of sebocyte function
  申请人：Wei Edward T.

  公开号：US20170240575A1

  公开（公告）日：2017-08-24

  The present discovery pertains to the discovery of certain amphiphilic compounds that may be useful for the management of sebum secretion in subjects with acne, oily skin, or seborrheic dermatitis. These compounds are 1-dialkylphosphorylalkanes with the longest alkyl group being seven or more carbons. Preferably, a compound is dissolved in a dermatologically acceptable vehicle, and delivered to the skin in a solution, gel, lotion, cream, or ointment. The method of application may be with the surface of the finger, or via an applicator. The decrease is sebum secretion in certain subjects may result in skin conditions that enhance cosmetic appearance and ameliorate skin disorders.

  这项发现涉及到某些两性分子化合物的发现，这些化合物可能对患有痤疮、油性皮肤或脂溢性皮炎的人群的皮脂分泌管理有用。这些化合物是1-二烷基磷酰基烷烃，其中最长的烷基基团含有七个或更多碳原子。最好将化合物溶解在皮肤学上可接受的载体中，并以溶液、凝胶、乳液、霜剂或软膏的形式送达到皮肤上。应用方法可以是用手指表面，或通过一个涂抹器。减少某些人群的皮脂分泌可能导致增强化妆效果和改善皮肤疾病的皮肤状况。
• [EN] 1-DI(SEC-BUTYL)-PHOSPHINOYL-PENTANE (DAPA-2-5) AS A TOPICAL AGENT FOR THE TREATMENT OF DISCOMFORT FROM NON-KERATINIZED STRATIFIED EPITHELIAL (NKSE) TISSUE<br/>[FR] 1-DI(SEC-BUTYL)-PHOSPHINOYL-PENTANE (DAPA-2-5) EN TANT QUE MÉDICAMENT TOPIQUE POUR LE TRAITEMENT DE L'INCONFORT DU TISSU ÉPITHÉLIAL STRATIFIÉ NON KÉRATINISÉ
  申请人：WEI EDWARD TAK

  公开号：WO2015059433A1

  公开（公告）日：2015-04-30

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to a particular di-alkyl-phosphinoyl- alkane, 1-di(sec-butyl)-phosphinoyl-pentane, referred to herein as "DAPA-2-5". Surprisingly and unexpectedly, DAPA-2-5, is able to treat (e.g., suppress) sensory discomfort from non-keratinized stratified epithelium (NKSE) selectively, that is, without the problems of stinging or irritancy, for example, as found with structurally similar compounds. As described herein, DAPA-2-5 is able to evoke a dynamic cooling sensation on non-keratinized body surfaces (including, e.g., nasopharyngeal, oropharyngeal, pharyngeal, esophageal, and anogenital surfaces) which is not accompanied by stinging or other irritative sensations. Consequently, DAPA-2-5 is useful, for example, in the treatment of disorders (e.g., diseases) including sensory discomfort from non-keratinized stratified epithelial (NKSE) tissue; upper aerodigestive tract discomfort; oropharyngeal discomfort; esophageal discomfort; throat irritation; 15 cough; heartburn; chest pain; anogenital discomfort; or inflammation of non-keratinized stratified epithelial (NKSE) tissue. The present invention also pertains to pharmaceutical compositions comprising DAPA-2-5, and the use of DAPA-2-5 and DAPA-2-5 compositions, for example, in therapy.

  本发明涉及治疗化合物领域。更具体地，本发明涉及一种特定的二烷基膦酰基烷，1-二(正丁基)-膦酰基-戊烷，此处称为“DAPA-2-5”。令人惊讶和意外的是，DAPA-2-5能够选择性地治疗（例如抑制）非角化分层上皮（NKSE）的感觉不适，即，没有刺痛或刺激性问题，例如与结构相似的化合物发现的问题。如本文所述，DAPA-2-5能够在非角化体表面（包括例如鼻咽、口咽、咽部、食管和肛门表面）上引起动态冷却感觉，而不伴随刺痛或其他刺激性感觉。因此，DAPA-2-5在治疗疾病方面具有用途，例如治疗非角化分层上皮（NKSE）组织的感觉不适；上呼吸道消化道不适；口咽不适；食管不适；喉部刺激；咳嗽；胃灼热；胸痛；肛门不适；或非角化分层上皮（NKSE）组织的炎症。本发明还涉及包含DAPA-2-5的药物组合物，以及在治疗中使用DAPA-2-5和DAPA-2-5组合物的用途。
• Ophthalmic compositions and method for treating eye discomfort and pain
  申请人：Wei T. Edward

  公开号：US20050059639A1

  公开（公告）日：2005-03-17

  Eye discomfort is reduced by administering drops of an inventive composition containing a trialkyl phosphine oxide in an ophthalmic solution. The preferred method of administration is to drip the solution onto the medial canthus of the closed eye and to keep the eye closed until at least one minute after instillation. The preferred trialkyl phosphine oxide is selected for potency, long duration of action, and the absence of irritancy. A hydrocarbon polyol or a similar demulcent may be added to the composition in order to further reduce irritancy. The concentration of the trialkyl phosphine oxide in the ophthalmic solution is preferably in an amount of at least about 0.001 wt. % to about 0.5% (10 μg/ml to 5 mg/ml) of the composition.

  通过给眼科溶液滴加含有三烷基氧化膦的创新组合物的眼药水，可以减少眼部不适。首选的给药方法是将溶液滴在闭合眼睛的内眼角，并保持眼睛闭合至少一分钟。优选的三烷基氧化膦是因为其强效性、长效性和无刺激性而被选择。为了进一步减少刺激性，可以向组合物中添加碳氢化合物聚醇或类似的润滑剂。在眼科溶液中的三烷基氧化膦的浓度最好在至少约0.001重量％至约0.5％（10μg/ml至5毫克/毫升）的组合物中。
• Cooling adjunct for medications to treat disorders in the nasal cavity
  申请人：Wei Edward Tak

  公开号：US10722477B2

  公开（公告）日：2020-07-28

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.

  本发现一般涉及治疗化合物领域。更具体地说，本发现涉及本文所述的某些二烷基膦酰基烷烃、DIPA-1-8 和 DIPA-1-9，以及本文统称为 "DAPA 化合物 "的 2-6 和 2-7，这些化合物可用于治疗包括鼻腔感觉不适（如由炎症、刺激、瘙痒或疼痛引起）在内的紊乱（如疾病）。申请人发现，局部给药 DAPA 化合物与鼻内类固醇或鼻内抗组胺药结合使用，可立即缓解鼻腔不适，并提高患者使用鼻腔药物的依从性。